News

Press releases

Piers Morgan Joins Pharnext’s Board of Directors

July 15, 2021

Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

July 12, 2021

Shareholder Letter - June 2021

June 21, 2021

Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

June 7, 2021

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

April 28, 2021

Pharnext Reports Financial Results for Year-End 2020

April 27, 2021

Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

March 31, 2021

Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors; European Investors Also Provide Indication of Interest for an Additional Amount of up to €25 Million in Convertible Bonds

February 4, 2021

Pharnext Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

February 1, 2021

Pharnext 2019 Universal Registration Document Approved by AMF

November 10, 2020